This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Arch Biopartners Inc.
Drug Names(s): AB 569 , AB-569 , sodium nitrite + ethylenediaminetetraacetic acid
Description: AB569 is a fixed-dose combination of sodium nitrite and ethylenediaminetetraacetic acid (EDTA). AB569 constitutes a bactericidal method to treat mucoid and nonmucoid P. aeruginosa pulmonary infections that are resistant to traditional antibiotics. Preclinical studies showed that mucoid bacteria perish during anaerobic exposure to 15 mM nitrite (NO2–) at pH 6.5, which mimics CF airway mucus. Killing required a pH lower than 7, implicating formation of nitrous acid (HNO2) and NO, that adds NO equivalents to cellular molecules.
Arch and University of Cincinnati (UC)
In March 2015, Arch entered into a one year option agreement with UC to exclusively license the commercial rights to a pending U.S. Patent for the new drug treatment. Arch and UC have also extended for another year the existing option to license the commercial rights to a related U.S. Patent for treating bacterial respiratory infections using acidified nitrite.
In March 2016, Arch Biopartners entered into an exclusive license agreement with the University of Cincinnati (UC) for AB569. Arch will pay UC a nominal one time fee for entering into the license. All other future payments are consistent with industry standard and will be based on clinical trial and revenue milestones reached by Arch in future.
Additional information available to subscribers only: